New combo therapy aims to boost immune response in hard-to-treat lung cancer

NCT ID NCT07027514

Recruiting now Disease control Sponsor: Ankyra Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including those who have already tried standard treatments and those who have not yet been treated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Hospital
RECRUITING

Detroit, Michigan, 48201, United States
Community Health Network
RECRUITING

Indianapolis, Indiana, 46256, United States
FirstHealth of the Carolinas
RECRUITING

Pinehurst, North Carolina, 28374, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.